The ATM creates persistent overhang — any rally toward $2+ will likely be capped by the company's ability to sell shares into strength. Monitor daily volume for ATM sales disclosures in subsequent filings. The $184M cash runway suggests no immediate need to tap the facility, but the shelf signals management's willingness to dilute. Watch for any prospectus supplement that would indicate active ATM usage.
Price Chart
Executive Summary
Milestone Pharmaceuticals filed a $300M universal shelf registration (S-3) on May 13, 2026, including a $100M at-the-market (ATM) facility with Cantor Fitzgerald. The filing comes on the same day as Q1 2026 earnings showing $0.2M in initial CARDAMYST revenue but a widened net loss of $26.1M. With $184.2M cash providing runway into H2 2027, this shelf appears opportunistic to fund commercial launch and AFib-RVR development rather than a distress raise, but the potential for up to 44% dilution at current prices is significant.
Key Financial Metrics
Key Facts
- Shelf registration for up to $300M in securities, including a $100M ATM with Cantor Fitzgerald at 3.0% commission
- Q1 2026 product revenue of $0.2M from CARDAMYST launch; net loss widened to $26.1M ($0.20/share) from $20.8M ($0.31/share)
- Cash balance of $184.2M provides runway into H2 2027
- At $1.90/share, full ATM draw would add 52.6M shares, diluting existing holders by ~44%
- Outstanding convertible notes, pre-funded warrants, and common warrants represent additional overhang of ~83M potential shares
- No specific use of proceeds stated beyond working capital and general corporate purposes
Financial Impact
Up to $300M in potential dilution; full $100M ATM draw at $1.90/share would add 52.6M shares (44% dilution vs 117.8M outstanding)
Risk Factors
- Up to 44% dilution from full ATM draw at current prices
- Additional overhang from ~83M shares underlying convertible notes and warrants
- Commercial launch expenses are burning cash faster than initial revenue generation
- No specific use of proceeds creates uncertainty about capital allocation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-060391 |
| Document: tm2614252d2_ex4-3.htm | 0001104659-26-060391 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.6436 (−46.37%) |
Aug 21, 2026 9w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.6436 (−39.00%) |
Aug 12, 2026 10w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.6436 (+42.79%) |
May 26, 2026 21w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.6436 (+54.03%) |
May 13, 2026 23w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.6436 (+60.52%) |
May 13, 2026 23w ago | 8-K | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6436 (−62.58%) |
May 13, 2026 23w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6436 (−62.58%) |
Mar 20, 2026 31w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.6436 (−52.68%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.6436 (−61.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers